Page last updated: 2024-08-21

azomycin and sq 109

azomycin has been researched along with sq 109 in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (27.27)29.6817
2010's8 (72.73)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Spigelman, MK1
Zhang, Y1
Mancera, RL; Rivers, EC1
Nuermberger, EL; Spigelman, MK; Yew, WW1
Campbell, S; Jakubiec, W; Ladutko, L; Miller, PF; Mitton-Fry, M; Paige, D; Silvia, A; Wallis, RS1
Cole, ST; Hartkoorn, RC; Lechartier, B1
Elamin, AA; Singh, M; Stehr, M1
Jeong, BH; Koh, WJ; Kwon, YS1
Chang, KC; Heyckendorf, J; Lange, C; Olaru, ID; von Groote-Bidlingmaier, F; Yew, WW1
Chopra, S; Dasgupta, A; De Groote, MA; Soni, I1
Nair, SG; Patel, DB; Patel, HD; Rathwa, SK; Vasava, MS1

Reviews

9 review(s) available for azomycin and sq 109

ArticleYear
New tuberculosis therapeutics: a growing pipeline.
    The Journal of infectious diseases, 2007, Aug-15, Volume: 196 Suppl 1

    Topics: Adamantane; Animals; Antitubercular Agents; Clinical Trials as Topic; Diamines; Diarylquinolines; Ethylenediamines; Fluoroquinolones; Humans; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Tuberculosis

2007
Advances in the treatment of tuberculosis.
    Clinical pharmacology and therapeutics, 2007, Volume: 82, Issue:5

    Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Drugs, Investigational; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin; Treatment Refusal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary

2007
New anti-tuberculosis drugs with novel mechanisms of action.
    Current medicinal chemistry, 2008, Volume: 15, Issue:19

    Topics: Adamantane; Animals; Antitubercular Agents; Diarylquinolines; Drug Design; Drug Resistance, Multiple, Bacterial; Ethylenediamines; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Quinolines; Structure-Activity Relationship; Tuberculosis, Pulmonary

2008
Current development and future prospects in chemotherapy of tuberculosis.
    Respirology (Carlton, Vic.), 2010, Volume: 15, Issue:5

    Topics: Adamantane; Animals; Antitubercular Agents; Carbapenems; Clinical Trials as Topic; Diarylquinolines; Drug Delivery Systems; Ethylenediamines; Fluoroquinolones; Humans; Isonicotinic Acids; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Patient Compliance; Pyrroles; Quinolines; Rifamycins; Tuberculosis, Pulmonary

2010
Filling the pipeline - new drugs for an old disease.
    Current topics in medicinal chemistry, 2014, Volume: 14, Issue:1

    Topics: Adamantane; Antitubercular Agents; Cyclic GMP-Dependent Protein Kinases; Diarylquinolines; Enzymes; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Humans; Molecular Targeted Therapy; Mycobacterium tuberculosis; Nitroimidazoles; Quantitative Structure-Activity Relationship

2014
Tuberculosis: clinical trials and new drug regimens.
    Current opinion in pulmonary medicine, 2014, Volume: 20, Issue:3

    Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant

2014
Novel drugs against tuberculosis: a clinician's perspective.
    The European respiratory journal, 2015, Volume: 45, Issue:4

    Topics: Adamantane; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarylquinolines; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Female; Follow-Up Studies; Humans; Male; Nitroimidazoles; Oxazoles; Oxazolidinones; Treatment Outcome; Tuberculosis, Multidrug-Resistant

2015
Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria.
    Journal of medical microbiology, 2016, Volume: 65, Issue:1

    Topics: Adamantane; Aminopyridines; Anti-Bacterial Agents; Azepines; Benzamides; Clinical Trials as Topic; Diarylquinolines; Drug Discovery; Ethylenediamines; Fluoroquinolones; Humans; Minocycline; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Nontuberculous Mycobacteria; Oxazoles; Piperazines; Spiro Compounds; Thiazines; Tigecycline; Uridine

2016
Development of new drug-regimens against multidrug-resistant tuberculosis.
    The Indian journal of tuberculosis, 2019, Volume: 66, Issue:1

    Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Development; Drug Therapy, Combination; Duration of Therapy; Ethambutol; Ethylenediamines; Humans; Isoniazid; Macrolides; Medication Adherence; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant

2019

Other Studies

2 other study(ies) available for azomycin and sq 109

ArticleYear
Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Monitoring; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Quinolines; Reproducibility of Results; Time Factors

2012
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:11

    Topics: Adamantane; Antitubercular Agents; Aza Compounds; Diarylquinolines; Drug Combinations; Drug Synergism; Ethambutol; Ethylenediamines; Fluoroquinolones; Isoniazid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Spiro Compounds; Thiazines; Thienamycins

2012